Your Discovery Download for January
New complex brain cell models, a fresh partnership for ADCs, syngeneic model characterization, and in vitro brain permeability prediction...
Stay in the loop with the Discovery Download!
New Complex Cell Models for Neuroscience Drug Discovery
Complex brain cell culture models, with two, three, or four cell types cultured together, enable a deeper understanding of their interplay and therapeutic targeting of those connections. We have established and validated, for example, co-culture models of neurons and oligodendrocytes to investigate myelination and multiple sclerosis, and also a neuroinflammatory model using neurons, microglia, and astrocytes.
These models can be combined with various readouts and technologies to better mimic your disease state of interest and improve translational success in drug discovery.
New Efficacy Data Presentation of Syngeneic Models for Immuno-Oncology Drug Development
Syngeneic models are a critical tool in the field of immuno-oncology, allowing efficacy assessment of cancer immunotherapies within an intact immune system. Multiple factors may affect which syngeneic model is the most suitable for each project, including the model's responsiveness to immune-modulating therapies, the composition and extent of tumor-infiltrating leukocytes, and the overall immunogenicity of the tumor.
To make the choice easier, we provide new, broader characterization data with detailed information on our syngeneic models, providing valuable insights into their use and effectiveness in immunotherapy research.
New Partnership: Accelerate Antibody Drug Conjugate (ADC) Discovery and Development with NJ Bio
Charles River has partnered with NJ Bio, a contract research organization specializing in integrated chemistry and bioconjugation services, to expedite clients’ antibody drug conjugate (ADC) development from concept to clinic. The strategic alliance combines Charles River’s end-to-end ADC discovery services with NJ Bio’s bioconjugation and manufacturing capabilities.
An Optimized Approach to Predicting a Drug’s CNS Permeation Using In Vitro Data
The right in vitro screening assays can reliably predict a drug’s brain exposure early in the screening funnel, enabling the triaging of potential new chemical entities (NCEs) before they can progress into costlier in vivo assays. Reliable brain exposure prediction is key, especially if the therapeutic target is in the central nervous system, to avoid potential CNS side-effects in case of peripheral drugs.
As the usefulness of an in vitro system depends on its predictive performance and translatability, our team aimed to optimize existing in vitro transporter assays to improve CNS permeation prediction and data quality.
领英推荐
Webinar: One-Step Multi-Parameter Antibody Optimization
Antibody-based drugs are able to target a wide range of antigens, but many candidates require additional engineering for optimal therapeutic efficacy in humans. Our Tumbler? platform offers customizable antibody optimization validated across a diverse set of targets using a CDR-shuffling approach. This webinar introduces how library-based antibody engineering can maximize functional diversity and provide further functional insight, as well as reviews how antibody optimization fits within end-to-end antibody discovery.
Interview: What is the State of the Industry for Alternative Models?
Charles River launched the Alternative Methods Advancement Project (AMAP) in April 2024, giving a new structural framework to our efforts in researching and promoting alternatives to animal testing. The initiative focuses on pursuing scientific and technological innovation to enhance and accelerate the development of alternatives to the use of animals in evaluation of therapeutic products.
Over the last four years, we have spent $200 million on alternatives research, and part of the AMAP plan dedicated another $300 million over the next five years. Julie Frearson, SVP and Chief Scientific Officer, reflects on the first six months of the project since its official launch, and discusses ongoing efforts, key developments, and future plans.
Insight : Blood, Sweat, and Standardization in the Laboratory
The relentless march of scientific progress hinges on reliable data. In preclinical research, flow cytometry has proven to be a customizable tool that answers pharmacodynamic and biomarker-driven questions and dissects the complexities of cellular populations with laser-like precision. By analyzing light scatter and fluorescence, researchers can identify and characterize specific cell types, a crucial step in understanding disease processes and developing new drugs. Additionally, flow cytometrists have come together and agreed on basic best practices pertaining to instrumentation and assay validation. However, a shadow lurks within this realm: the specter of data variability.
SLAS2025 International Conference & Exhibition
January 25th - 29th, 2025. San Diego, CA. Booth #1343.
Join us at SLAS2025, the?conference designed to connect scientists with each other and with the laboratory technology and automation needed to transform life sciences research. Discover our latest technology and developments to support your discovery and development projects. Visit our poster, and be sure to attend our Solutions Spotlight Presentation (Booth 2907), on Tuesday the 28th, 12.30pm – 12.50pm.